John Rosendahl Østergaard

The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome. / Meinhardt, U; Christiansen, J S; Farholt, Stense; Lämmer, C; Ostergaard, J R; Schmidt, F; Kappelgaard, A-M; Eiholzer, U.

In: Hormone and Metabolic Research, 30.04.2013.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Meinhardt, U, Christiansen, JS, Farholt, S, Lämmer, C, Ostergaard, JR, Schmidt, F, Kappelgaard, A-M & Eiholzer, U 2013, 'The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome', Hormone and Metabolic Research. https://doi.org/10.1055/s-0033-1343449

APA

Meinhardt, U., Christiansen, J. S., Farholt, S., Lämmer, C., Ostergaard, J. R., Schmidt, F., Kappelgaard, A-M., & Eiholzer, U. (2013). The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome. Hormone and Metabolic Research. https://doi.org/10.1055/s-0033-1343449

CBE

Meinhardt U, Christiansen JS, Farholt S, Lämmer C, Ostergaard JR, Schmidt F, Kappelgaard A-M, Eiholzer U. 2013. The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome. Hormone and Metabolic Research. https://doi.org/10.1055/s-0033-1343449

MLA

Vancouver

Meinhardt U, Christiansen JS, Farholt S, Lämmer C, Ostergaard JR, Schmidt F et al. The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome. Hormone and Metabolic Research. 2013 Apr 30. https://doi.org/10.1055/s-0033-1343449

Author

Meinhardt, U ; Christiansen, J S ; Farholt, Stense ; Lämmer, C ; Ostergaard, J R ; Schmidt, F ; Kappelgaard, A-M ; Eiholzer, U. / The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome. In: Hormone and Metabolic Research. 2013.

Bibtex

@article{448337663768462089e77dc252960356,
title = "The Efficacy and Safety of Long-term Norditropin{\textregistered} Treatment in Children with Prader-Willi Syndrome",
abstract = "Prader-Willi syndrome is a genetic disorder that is associated with short stature, partial growth hormone deficiency, small hands and feet, learning and behavioural problems, and hyperphagia leading to severe, often morbid, obesity. Growth hormone therapy is associated with an improvement in height and body composition. We evaluated the efficacy and safety of long-term growth hormone treatment in a retrospective observational multinational study of 41 prepubertal children (mean age 3.8±3.0 years) with genetically diagnosed Prader-Willi syndrome treated with growth hormone (0.03-0.06 mg/kg/day) for >12 months [mean duration 4.1 (range 0.9-9.5) years]. Height, weight, and body composition measurements were recorded at baseline and at 6 month intervals until last observation. Mean (SD) gain in height at 12 months was 0.9 (0.2) SD score (p- 2 SD score. Body composition improved during treatment with an estimated 9.1% increase in lean body mass and 9.1% decrease in fat mass at last observation (p=0.019). Scoliosis was reported in 3 patients at baseline and 8 patients at last observation. Sleep apnoea was recorded in 3 (7.3%) patients. There were no other severe adverse events reported. Long-term growth hormone treatment of prepubertal children with Prader-Willi syndrome was associated with significant improvements in height and body composition. Treatment was well tolerated. The development of scoliosis warrants monitoring by an orthopaedic specialist.",
author = "U Meinhardt and Christiansen, {J S} and Stense Farholt and C L{\"a}mmer and Ostergaard, {J R} and F Schmidt and A-M Kappelgaard and U Eiholzer",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2013",
month = apr,
day = "30",
doi = "10.1055/s-0033-1343449",
language = "English",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "GeorgThieme Verlag",

}

RIS

TY - JOUR

T1 - The Efficacy and Safety of Long-term Norditropin® Treatment in Children with Prader-Willi Syndrome

AU - Meinhardt, U

AU - Christiansen, J S

AU - Farholt, Stense

AU - Lämmer, C

AU - Ostergaard, J R

AU - Schmidt, F

AU - Kappelgaard, A-M

AU - Eiholzer, U

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2013/4/30

Y1 - 2013/4/30

N2 - Prader-Willi syndrome is a genetic disorder that is associated with short stature, partial growth hormone deficiency, small hands and feet, learning and behavioural problems, and hyperphagia leading to severe, often morbid, obesity. Growth hormone therapy is associated with an improvement in height and body composition. We evaluated the efficacy and safety of long-term growth hormone treatment in a retrospective observational multinational study of 41 prepubertal children (mean age 3.8±3.0 years) with genetically diagnosed Prader-Willi syndrome treated with growth hormone (0.03-0.06 mg/kg/day) for >12 months [mean duration 4.1 (range 0.9-9.5) years]. Height, weight, and body composition measurements were recorded at baseline and at 6 month intervals until last observation. Mean (SD) gain in height at 12 months was 0.9 (0.2) SD score (p- 2 SD score. Body composition improved during treatment with an estimated 9.1% increase in lean body mass and 9.1% decrease in fat mass at last observation (p=0.019). Scoliosis was reported in 3 patients at baseline and 8 patients at last observation. Sleep apnoea was recorded in 3 (7.3%) patients. There were no other severe adverse events reported. Long-term growth hormone treatment of prepubertal children with Prader-Willi syndrome was associated with significant improvements in height and body composition. Treatment was well tolerated. The development of scoliosis warrants monitoring by an orthopaedic specialist.

AB - Prader-Willi syndrome is a genetic disorder that is associated with short stature, partial growth hormone deficiency, small hands and feet, learning and behavioural problems, and hyperphagia leading to severe, often morbid, obesity. Growth hormone therapy is associated with an improvement in height and body composition. We evaluated the efficacy and safety of long-term growth hormone treatment in a retrospective observational multinational study of 41 prepubertal children (mean age 3.8±3.0 years) with genetically diagnosed Prader-Willi syndrome treated with growth hormone (0.03-0.06 mg/kg/day) for >12 months [mean duration 4.1 (range 0.9-9.5) years]. Height, weight, and body composition measurements were recorded at baseline and at 6 month intervals until last observation. Mean (SD) gain in height at 12 months was 0.9 (0.2) SD score (p- 2 SD score. Body composition improved during treatment with an estimated 9.1% increase in lean body mass and 9.1% decrease in fat mass at last observation (p=0.019). Scoliosis was reported in 3 patients at baseline and 8 patients at last observation. Sleep apnoea was recorded in 3 (7.3%) patients. There were no other severe adverse events reported. Long-term growth hormone treatment of prepubertal children with Prader-Willi syndrome was associated with significant improvements in height and body composition. Treatment was well tolerated. The development of scoliosis warrants monitoring by an orthopaedic specialist.

U2 - 10.1055/s-0033-1343449

DO - 10.1055/s-0033-1343449

M3 - Journal article

C2 - 23632904

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

ER -